Clinical significance of lipoarabinomannan detection in urine using a low-cost point-of-care diagnostic assay for HIV-associated tuberculosis

AIDS

Volumn 26, Issue 13, 2012, Pages 1635-1643

  Lawn, Stephen D ^a,b   Kerkhoff, Andrew D ^a,c   Vogt, Monica ^a   Wood, Robin ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

Author keywords

Africa; antiretroviral; diagnosis; HIV; LAM; lipoarabinomannan; screening; tuberculosis

Indexed keywords

ANTIRETROVIRUS AGENT; BACTERIAL ANTIGEN; LIPOARABINOMANNAN; TUBERCULOSTATIC AGENT;

ADULT; AFRICA; ANTIGEN DETECTION; ARTICLE; ASSAY; BACTERIAL CELL WALL; BACTERIUM CULTURE; CD4 LYMPHOCYTE COUNT; CLINICAL LABORATORY; COHORT ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LABORATORY TEST; LIQUID CULTURE; LOGISTIC REGRESSION ANALYSIS; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIVARIATE ANALYSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; OUTCOMES RESEARCH; POINT OF CARE TESTING; PREDICTIVE VALUE; PRIORITY JOURNAL; QUESTIONNAIRE; RETROSPECTIVE STUDY; SCREENING TEST; SPUTUM CULTURE; SYMPTOM; THORAX RADIOGRAPHY; TUBERCULOSIS; UNIVARIATE ANALYSIS; URINALYSIS; URINE LEVEL; VIRUS LOAD;

ADULT; CD4 LYMPHOCYTE COUNT; FEMALE; HIV SEROPOSITIVITY; HUMANS; LIPOPOLYSACCHARIDES; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; POINT-OF-CARE SYSTEMS; PROSPECTIVE STUDIES; SOUTH AFRICA; SPUTUM; TUBERCULOSIS;

EID: 84865494970     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e3283553685     Document Type: Article

References (30)

1. Lawn SD, Harries AD, Anglaret X, Myer L, Wood R. Early mortality among adults accessing antiretroviral treatment programmes in sub-Saharan Africa. AIDS 2008; 22:1897-1908.
2. Braitstein P, Brinkhof MW, Dabis F, Schechter M, Boulle A, Miotti P, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet 2006; 367:817-824.
3. Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS 2005; 19:2141-2148. (Pubitemid 41669003)
4. Lawn SD, Harries AD, Wood R. Strategies to reduce early morbidity and mortality in adults receiving antiretroviral therapy in resource-limited settings. Curr Opin HIV AIDS 2010; 5:18-26.
5. Lawn SD, Myer L, Bekker LG, Wood R. Burden of tuberculosis in an antiretroviral treatment programme in sub-Saharan Africa: impact on treatment outcomes and implications for tuberculosis control. AIDS 2006; 20:1605-1612. (Pubitemid 44162402)
6. Bassett IV, Wang B, Chetty S, Giddy J, Losina E, Mazibuko M, et al.Intensive tuberculosis screening for HIV-infected patients starting antiretroviral therapy in Durban, South Africa. Clin Infect Dis 2010; 51:823-829.
7. Lawn SD, Wood R. Tuberculosis in antiretroviral treatment services in resource-limited settings: addressing the challenges of screening and diagnosis. J Infect Dis 2011; 204 (Suppl 4): S1159-S1167.
8. World Health Organization. WHO three I's meeting. Report of a jointWHOHIV/AIDS and TB DepartmentMeeting, 2008. WHO, Geneva. Accessed on 12th Jan 2012 at: http://www.who.int/hiv/pub/meetingreports/WHO-3Is-meeting-report. pdf.
9. Kranzer K, Houben RM, Glynn JR, Bekker LG, Wood R, Lawn SD. Yield of HIV-associated tuberculosis during intensified case finding in resource-limited settings: a systematic review and meta-analysis. Lancet Infect Dis 2010; 10:93-102.
10. Lawn SD, Kranzer K, Edwards DJ, McNally M, Bekker LG, Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24:1323-1328.
11. Reid MJ, Shah NS. Approaches to tuberculosis screening and diagnosis in people with HIV in resource-limited settings. Lancet Infect Dis 2009; 9:173-184.
12. Dawson R, Masuka P, Edwards DJ, Bateman ED, Bekker LG, Wood R, et al. Chest radiograph reading and recording system: evaluation for tuberculosis screening in patients with advanced HIV.Int J Tuberc Lung Dis 2010; 14:52-58.
13. Lawn SD, Nicol MP. Xpert(R) MTB/RIF assay: development, evaluation and implementation of a new rapid molecular diagnostic for tuberculosis and rifampicin resistance. Future Microbiol 2011; 6:1067-1082.
14. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med 2010; 363:1005-1015.
15. Boehme CC, Nicol MP, Nabeta P, Michael JS, Gotuzzo E, Tahirli R, et al. Feasibility, diagnostic accuracy, and effectiveness of decentralised use of the Xpert MTB/RIF test for diagnosis of tuberculosis and multidrug resistance: a multicentre implementation study. Lancet 2011; 377:1495-1505.
16. WHO. Tuberculosis diagnostics automated DNA test. WHO endorsement and recommendations. World Health Organization, Geneva, 2010. Accessed on 12 Jan 2012 at: http://www.who.int/tb/features-archive/xpert-factsheet.pdf.
17. Trebucq A, Enarson DA, Chiang CY, Van Deun A, Harries AD, Boillot F, et al. Xpert(R) MTB/RIF for national tuberculosis programmes in low-income countries: when, where and how? Int J Tuberc Lung Dis 2011; 15:1567-1572.
18. Lawn SD, Brooks SV, Kranzer K, Nicol MP, Whitelaw A, Vogt M, et al. Screening for HIV-associated tuberculosis and rifampicin resistance before antiretroviral therapy using the Xpert MTB/RIF assay: a prospective study. PLoS Med 2011; 8: e1001067.
19. Lawn SD, Kerkhoff AD, Vogt M, Ghebrekristos Y, Whitelaw A, Wood R. Characteristics and early outcomes of patients with Xpert MTB/RIF-negative pulmonary tuberculosis diagnosed during screening before antiretroviral therapy. Clin Infect Dis 2012; 54:1071-1079.
20. Lawn SD, Kerkhoff AD, Wood R. Location of Xpert(R) MTB/RIF in centralised laboratories in South Africa undermines potential impact.Int J Tuberc Lung Dis 2012; 16:701.
21. Lawn SD, Kerkhoff AD, Vogt M, Wood R. Diagnostic accuracy of a low-cost, urine antigen, point-of-care screening assay for HIV-associated pulmonary tuberculosis before antiretroviral therapy: a descriptive study. Lancet Infect Dis 2012; 12:201-209.
22. Getahun H, Kittikraisak W, Heilig CM, Corbett EL, Ayles H, Cain KP, et al. Development of a standardized screening rule for tuberculosis in people living with HIV in resource-constrained settings: individual participant data meta-analysis of observational studies. PLoS Med 2011; 8:e1000391.
23. Den Boon S, Bateman ED, Enarson DA, Borgdorff MW, Verver S, Lombard CJ, et al. Development and evaluation of a new chest radiograph reading and recording system for epidemiological surveys of tuberculosis and lung disease.Int J Tuberc Lung Dis 2005; 9:1088-1096. (Pubitemid 41433798)
24. Lawn SD, Edwards DJ, Kranzer K, Vogt M, Bekker LG, Wood R. Urine lipoarabinomannan assay for tuberculosis screening before antiretroviral therapy diagnostic yield and association with immune reconstitution disease. AIDS 2009; 23:1875-1880.
25. Boehme C, Molokova E, Minja F, Geis S, Loscher T, Maboko L, et al. Detection of mycobacterial lipoarabinomannan with an antigen-capture ELISA in unprocessed urine of Tanzanian patients with suspected tuberculosis. Trans R Soc Trop Med Hyg 2005; 99:893-900. (Pubitemid 41511449)
26. Achkar JM, Lawn SD, Moosa MY, Wright CA, Kasprowicz VO. Adjunctive tests for diagnosis of tuberculosis: serology, ELISPOT for site-specific lymphocytes, urinary lipoarabinomannan, string test, and fine needle aspiration. J Infect Dis 2011; 204 (Suppl 4):S1130-S1141.
27. Minion J, Leung E, Talbot E, Dheda K, Pai M, Menzies D. Diagnosing tuberculosis with urine lipoarabinomannan: systematic review and meta-analysis. Eur Respir J 2011 [Epub ahead of print]
28. Shah M, Variava E, Holmes CB, Coppin A, Golub JE, McCallum J, et al. Diagnostic accuracy of a urine lipoarabinomannan test for tuberculosis in hospitalized patients in a High HIV prevalence setting. J Acquir Immune Defic Syndr 2009; 52:145-151; 29.
29. Lawn SD. Point-of-care detection of lipoarabinomannan (LAM) in urine for diagnosis of HIV-associated tuberculosis: a state of the art review. BMC Infect Dis 2012; 12:103.
30. Lawn SD, Myer L, Harling G, Orrell C, Bekker LG, Wood R. Determinants of mortality and nondeath losses from an antiretroviral treatment service in South Africa: implications for program evaluation. Clin Infect Dis 2006; 43:770-776. (Pubitemid 44330743)